Zoetis Inc. $ZTS Shares Sold by Eastern Bank

Eastern Bank decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 53.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,336 shares of the company’s stock after selling 11,639 shares during the quarter. Eastern Bank’s holdings in Zoetis were worth $1,300,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of ZTS. Halbert Hargrove Global Advisors LLC grew its stake in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares in the last quarter. Global Wealth Strategies & Associates purchased a new position in Zoetis in the 4th quarter worth approximately $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in Zoetis in the 3rd quarter worth approximately $31,000. Holos Integrated Wealth LLC acquired a new position in shares of Zoetis during the 4th quarter worth approximately $32,000. Finally, Financial Consulate Inc. purchased a new stake in shares of Zoetis in the third quarter valued at approximately $39,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Up 0.1%

ZTS stock opened at $113.48 on Monday. Zoetis Inc. has a one year low of $113.29 and a one year high of $172.23. The firm has a market cap of $47.90 billion, a PE ratio of 18.85, a PEG ratio of 1.73 and a beta of 0.95. The firm’s 50 day moving average price is $123.39 and its 200-day moving average price is $129.03. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several recent research reports. Barclays assumed coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target for the company. HSBC set a $140.00 target price on Zoetis in a report on Wednesday, December 10th. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a report on Monday, December 15th. Finally, Morgan Stanley set a $160.00 price target on shares of Zoetis in a research report on Thursday, December 18th. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zoetis presently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.